Both of these γδ T-cell subsets have been described to kill a variety of cancer cell lines upon activation of their specific TCRs, innate receptors like NKG2D, or by engaging the “death receptors” Fas or TRAIL on tumor cells (11–13). The gene discussed is FAS; the disease is neoplasm.